206 related articles for article (PubMed ID: 27103799)
1. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.
Han NK; Shin DH; Kim JS; Weon KY; Jang CY; Kim JS
Int J Nanomedicine; 2016; 11():1413-25. PubMed ID: 27103799
[TBL] [Abstract][Full Text] [Related]
2. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Effect of Immunoliposomal Gemcitabine and Bevacizumab in Glioblastoma Stem Cell-Targeted Therapy.
Shin DH; Lee SJ; Kim JS; Ryu JH; Kim JS
J Biomed Nanotechnol; 2015 Nov; 11(11):1989-2002. PubMed ID: 26554157
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
5. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z
J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-coated liposomes for active targeting of gemcitabine.
Arpicco S; Lerda C; Dalla Pozza E; Costanzo C; Tsapis N; Stella B; Donadelli M; Dando I; Fattal E; Cattel L; Palmieri M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):373-80. PubMed ID: 23791684
[TBL] [Abstract][Full Text] [Related]
7. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
8. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
Abd Al-Jabbar S; Atiroğlu V; Hameed RM; Guney Eskiler G; Atiroğlu A; Deveci Ozkan A; Özacar M
Bioorg Chem; 2022 Jan; 118():105467. PubMed ID: 34781115
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
[TBL] [Abstract][Full Text] [Related]
10. Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.
Paolino D; Licciardi M; Celia C; Giammona G; Fresta M; Cavallaro G
Eur J Pharm Biopharm; 2012 Sep; 82(1):94-102. PubMed ID: 22705641
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid conjugated multi-walled carbon nanotubes for colon cancer targeting.
Prajapati SK; Jain A; Shrivastava C; Jain AK
Int J Biol Macromol; 2019 Feb; 123():691-703. PubMed ID: 30445095
[TBL] [Abstract][Full Text] [Related]
13. Development of Liposomal Gemcitabine with High Drug Loading Capacity.
Tamam H; Park J; Gadalla HH; Masters AR; Abdel-Aleem JA; Abdelrahman SI; Abdelrahman AA; Lyle LT; Yeo Y
Mol Pharm; 2019 Jul; 16(7):2858-2871. PubMed ID: 31136710
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
15. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
[TBL] [Abstract][Full Text] [Related]
16. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
17. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
18. CD133 antibody-conjugated immunoliposomes encapsulating gemcitabine for targeting glioblastoma stem cells.
Shin DH; Xuan S; Kim WY; Bae GU; Kim JS
J Mater Chem B; 2014 Jun; 2(24):3771-3781. PubMed ID: 32261723
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo.
Tao XM; Wang JC; Wang JB; Feng Q; Gao SY; Zhang LR; Zhang Q
Eur J Pharm Biopharm; 2012 Oct; 82(2):401-9. PubMed ID: 22728546
[TBL] [Abstract][Full Text] [Related]
20. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
